Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 21;10(8):2045.
doi: 10.3390/biomedicines10082045.

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Eleni Triantafyllidi  1 , John K Triantafillidis  2
Affiliations
Review

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Eleni Triantafyllidi et al. Biomedicines. .

Abstract

Trastuzumab is a monoclonal antibody used in the treatment of breast cancer in cases where the tumor overexpresses the HER2 receptor, a cell membrane receptor activated by the epidermal growth factor. Intravenous and subcutaneous administration of trastuzumab have comparable clinical and pharmacological characteristics, but trastuzumab biosimilars are currently only available in intravenous form. Trastuzumab biosimilars are ultimately preferred by a proportion of patients, especially in cases where co-administration of other chemotherapeutic agents, such as trastuzumab and tucatinib, a small molecule of tyrosine kinase inhibitor, is required in patients with HER-positive metastatic breast cancer. Oncologists should be well-aware of the advantages of intravenously administered trastuzumab biosimilars over subcutaneous administration, certainly also taking into account the patient's preferences. Further cost-effectiveness analyses will be very important, along with expectations regarding successful concomitant subcutaneous administration of trastuzumab with other anticancer drugs, such as pertuzumab. This systematic review describes and analyzes the so-far published studies concerning the use of the available trastuzumab biosimilars in HER-positive early and metastatic breast cancer in terms of efficacy, safety, and cost-benefit ratio. An attempt was also made to draw some conclusions and to comment on future needs and perspectives.

Keywords: biosimilars; breast cancer; cost; monoclonal antibodies; trastuzumab; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flow Diagram.
See this image and copyright information in PMC

References

    1. Łukasiewicz S., Czeczelewski M., Forma A., Baj J., Sitarz R., Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers. 2021;13:4287. doi: 10.3390/cancers13174287. - DOI - PMC - PubMed
    1. Loibl S., Poortmans P., Morrow M., Denkert C., Curigliano G. Breast cancer. Lancet. 2021;397:1750–1769. doi: 10.1016/S0140-6736(20)32381-3. - DOI - PubMed
    1. European Medicines Agency: Similar Biological Medicinal Products CHMP/437/04 Rev. 1. 23 October 2014 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP) [(accessed on 6 March 2022)]. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin....
    1. European Medicines Agency: Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMEA/CHMP/BMWP/42832/2005 Rev. 1. 18 December 2014 EMEA/CHMP/BMWP/42832/2005 Rev1 Committee for Medicinal Products for Human Use (CHMP) [(accessed on 6 March 2022)]. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin....
    1. Jackisch C., Lammers P., Jacobs I. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast. 2017;32:199–216. doi: 10.1016/j.breast.2017.01.010. - DOI - PMC - PubMed